• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis.

作者信息

Esteban D, Tovar N, Jiménez R, Santacruz R, Baumann T, Pastor M C, de la Riva A, Carrera E, Chaves S, Royo C, Navarro A, Rodríguez S, Ayuso C, Riu G, Creus N, Gómez B, Giné E, López-Guillermo A, Delgado J

机构信息

Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.

Haematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain.

出版信息

Blood Cancer J. 2015 Oct 2;5(10):e356. doi: 10.1038/bcj.2015.78.

DOI:10.1038/bcj.2015.78
PMID:26430727
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4635190/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c99/4635190/f3c41a1bfbf3/bcj201578f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c99/4635190/f3c41a1bfbf3/bcj201578f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c99/4635190/f3c41a1bfbf3/bcj201578f1.jpg

相似文献

1
Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis.复发/难治性慢性淋巴细胞白血病患者无论接受何种治疗，纳入临床试验可能均有益处：一项病例对照回顾性分析
Blood Cancer J. 2015 Oct 2;5(10):e356. doi: 10.1038/bcj.2015.78.
2
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.氟达拉滨和环磷酰胺联合阿仑单抗治疗原发性高危、复发或难治性慢性淋巴细胞白血病患者。
Leukemia. 2012 Dec;26(12):2549-52. doi: 10.1038/leu.2012.129. Epub 2012 May 15.
3
Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.利妥昔单抗联合大剂量地塞米松治疗复发/难治性慢性淋巴细胞白血病。
Leuk Res. 2012 Oct;36(10):1278-82. doi: 10.1016/j.leukres.2012.07.005. Epub 2012 Jul 25.
4
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.一项关于在复发/难治性慢性淋巴细胞白血病患者中常规临床应用低剂量阿仑单抗的意大利回顾性研究。
Br J Haematol. 2012 Feb;156(4):481-9. doi: 10.1111/j.1365-2141.2011.08965.x. Epub 2011 Dec 9.
5
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.阿仑单抗（抗CD52单克隆抗体）作为复发/难治性慢性淋巴细胞白血病（CLL）患者的单药治疗——对连续患者的单区域经验
Ann Hematol. 2014 Oct;93(10):1725-33. doi: 10.1007/s00277-014-2105-1. Epub 2014 May 21.
6
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.异体造血干细胞移植后基于风险分层的过继性细胞治疗晚期慢性淋巴细胞白血病。
Br J Haematol. 2013 Mar;160(5):640-8. doi: 10.1111/bjh.12197. Epub 2013 Jan 7.
7
Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.复发性慢性淋巴细胞白血病的治疗：新旧疗法
Semin Oncol. 2006 Apr;33(2):210-9. doi: 10.1053/j.seminoncol.2006.01.012.
8
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.氟达拉滨联合环磷酰胺加或不加奥布利默森钠（Bcl-2反义核酸）治疗复发或难治性慢性淋巴细胞白血病的随机III期试验。
J Clin Oncol. 2007 Mar 20;25(9):1114-20. doi: 10.1200/JCO.2006.07.1191. Epub 2007 Feb 12.
9
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.低剂量皮下注射阿仑单抗治疗难治性慢性淋巴细胞白血病（CLL）：一项前瞻性单臂多中心研究的结果
Leukemia. 2009 Nov;23(11):2027-33. doi: 10.1038/leu.2009.148. Epub 2009 Jul 30.
10
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.阿仑单抗在经过大量预处理的B细胞慢性淋巴细胞白血病患者中的常规临床应用：奥地利一项全国性回顾性研究
Cancer. 2006 Nov 15;107(10):2408-16. doi: 10.1002/cncr.22263.

本文引用的文献

1
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.进入慢性淋巴细胞白血病的靶向治疗时代：对临床执业医师的影响
J Clin Oncol. 2014 Sep 20;32(27):3039-47. doi: 10.1200/JCO.2014.55.8262.
2
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.伊布替尼与奥法妥木单抗治疗既往治疗的慢性淋巴细胞白血病。
N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
3
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
单中心靶向治疗对复发的del(17p13.1)核型慢性淋巴细胞白血病患者预后的影响
Leukemia. 2014 Jun;28(6):1365-8. doi: 10.1038/leu.2014.42. Epub 2014 Jan 23.
4
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.依鲁替尼联合利妥昔单抗治疗复发慢性淋巴细胞白血病。
N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.
5
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
6
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.一项观察性研究，评估在 Medicare 诊断为慢性淋巴细胞白血病的患者中初始输注治疗后的结局。
Blood. 2011 Mar 31;117(13):3505-13. doi: 10.1182/blood-2010-08-301929. Epub 2010 Dec 29.
7
A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.紧迫感评估：评估临床试验开发时间与癌症治疗评估计划（NCI-CTEP）赞助研究累积表现之间的关系。
Clin Cancer Res. 2010 Nov 15;16(22):5557-63. doi: 10.1158/1078-0432.CCR-10-0133. Epub 2010 Nov 9.
8
Availability of experimental therapy outside oncology randomized clinical trials in the United States.美国肿瘤学以外的实验疗法在随机临床试验中的可及性。
J Clin Oncol. 2010 Dec 1;28(34):5067-73. doi: 10.1200/JCO.2010.28.6567. Epub 2010 Oct 25.
9
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.利妥昔单抗联合氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病患者的随机、开放标签、3 期临床试验。
Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.
10
Project Zero Delay: a process for accelerating the activation of cancer clinical trials.零延迟项目：加速癌症临床试验启动的流程。
J Clin Oncol. 2009 Sep 10;27(26):4433-40. doi: 10.1200/JCO.2008.21.6093. Epub 2009 Aug 3.